Applications:

FA

Synonyms:

SB-525334, 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline

Formulation:

Crystalline solid

Chemical Name:

6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline

Molecular Formula:

C₂₁H₂₁N₅

Molecular Weight:

<div "class="productview-attribute-conten_div" style="margin: 0px; padding: 0px;">343.4

CAS Number

356559-20-1

Purity:

≥98%

Storage Conditions:

Product should be kept at -20°C.

References:

Higashiyama, H., Yoshimoto, D., Kaise, T., Matsubara, S., Fujiwara, M., Kikkawa, H., ... & Kinoshita, M. (2007). Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.Experimental and molecular pathology,83(1), 39-46.

Grygielko, E. T., Martin, W. M., Thornton, P., Tweed, C., & Laping, N. J. (2002, September). SB-525334, a novel TGF-beta type I receptor kinase inhibitor in the puromycin aminonucleoside model of renal disease. InJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY(Vol. 13, pp. 5A-5A). 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS.

Underwood, D. C., Osborn, R. R., Grygielko, E. T., & Laping, N. J. (2003). SB-525334, a novel TGF-beta type 1 receptor kinase inhibitor, prevents ans reverses Bleopmycin-induced pulmonary fibrosis in the rat.